Cancer immunotherapy using immune-checkpoint blockade (ICB) has created a paradigm
shift in the treatment of advanced-stage cancers. The promising antitumour activity of …

The clinical development of checkpoint inhibitor-based immunotherapy has ushered in an
exciting era of anticancer therapy. Durable responses can be seen in patients with …

Immune checkpoint blockade (ICB) has heralded a new era in cancer therapy. Research
into the mechanisms underlying response to ICB has predominantly focused on T cells; …

Objectives Immunotherapy with the programmed death receptor-1 (PD-1) antibody
nivolumab has changed the field of metastatic non-small cell lung cancer (NSCLC) …

Clinical trials with immune checkpoint inhibitors have provided important insights into the
mode of action of anticancer immune therapies and potential mechanisms of immune …

Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte–
associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD …

The impact of cancer immunotherapy on clinical cancer care is growing rapidly. However,
different immunotherapies remedy distinct problems in cancer–immune system interactions …

Immune checkpoint inhibitors (ICIs) are a novel class of immunotherapy drugs that have
improved the treatment of a broad spectrum of cancers as metastatic melanoma, non-small …

Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), programed cell
death 1 (PD-1), or its ligand (PD-L1) have become the mainstay for advanced malignancies …

Purpose: Biomarkers for outcome after immune-checkpoint blockade are strongly needed as
these may influence individual treatment selection or sequence. We aimed to identify …